OSLO and MCC are part of a therapeutic discovery approach developed by Beech Tree Labs. This novel avenue for restoring homeodynamics is known as Resonant Molecular Signaling (RMS), a platform characterized by administration of low concentrations of precisely selected and dosed molecules resulting in efficacy with placebo-level adverse effects.

The pathogeneses of diseases involve cascades of events induced by causative agent(s) that disrupt intracellular and intercellular signaling. Based on genomic, proteomic, and clinical evaluations, RMS formulations restore homeodynamics by up- and/or down-regulating genes involved in complex protein pathways, thereby reversing or eliminating one or more of the inappropriate signals and re-establishing normal biological communication.

In the case of chronic traumatic brain injury, OSLO leads to measurable and repeatable physiological responses in distant body organs, including the brain. This method is validated and has been reported in peer-reviewed journals addressing the mechanism of action and clinical efficacy of OSLO.1-5

For hypermobile Ehlers-Danlos Syndromes, MCC is a combination of repurposed molecules known to physicians and the FDA that, according to anecdotal evidence, may reverse symptoms such as pain and fatigue. There is also evidence that MCC may improve joint movement and function.

The following diagram demonstrates the process of RMS therapy.

RMS Restores Normal Communication Between and Among Cells


  1. Gurel V, Lambert K, Page AE, Loynachan AT, Hughes K, Timoney JF, Fettinger M, Horohov DW, McMichael J. “Streptolysin-O/Antibiotics Adjunct Therapy Modulates Site-specific Expression of Extracellular Matrix and Inflammatory Genes in Lungs of Rhodococcus equi Infected Foals,” Veterinary Research Communications, 37(2):145-54 , March 2013.
  2. Horohov DW, Loynachan AT, Page AE, Hughes K, Timoney JF, Fettinger M, Hatch T, Spaulding JG, McMichael J.T “he use of streptolysin O (SLO) as an adjunct therapy for Rhodococcus equi pneumonia in foals,”  Veterinary Microbiology, 154:156–162, 2011.
  3. Mamber SW, Gurel V, Rhodes RG, McMichael J. “Effects of Streptolysin O on Extracellular Matrix Gene Expression in Normal Human Epidermal Keratinocytes,” Dose-Response, 9:554-578, 2011.
  4. M Tomic-Canic M, SW Mamber SW, O Stojadinovic O, Lee B, Radoja N, McMichael J. “Streptolysin O enhances keratinocyte migration and proliferation and promotes skin organ culture wound healing in vitro.”  Wound Repair and Regeneration, 15(1):71-79, 2007.
  5. Mamber SW, Long V, Rhodes RG, Pond-Tor S, Wheeler LR, Fredericks K, Vanscoy B, Sauniere J. F, Steinschneider R, Laurent J. C, McMichael J. “The use of streptolysin O for the treatment of scars, adhesions and fibrosis: Initial investigations using murine models of scleroderma.”  Nonlinearity in Biology, Toxicology and Medicine, 2(2):67-87, Apr-Jun 2004.